Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)

#2235

Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.

Aim(s): To correlate the efficacy of sunitinib with clinical, radiological variables and with dose-intensity and treatment time.

Materials and methods: CRIPNET is a prospective, multicenter (9 medical oncology department), noninterventional study carried out between 2015 and 2017 by the Spanish group of neuroendocrine tumours (GETNE). Patients had progressive, advanced, grade 1-2, PNETs before start of sunitinib.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Jimenez-Fonseca P, Solis Hernandez M, Fernandez del Valle A, Garcia-Carbonero R, Matos I,

Keywords: PNET, sunitinib, dose-intensive, progression-free survival,